Nipocalimab-aahu (Imaavy) | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 1083 covering nipocalimab-aahu (Imaavy), effective April 2, 2026. Here's what billing teams need to know before submitting claims for this newly approved biologic.

Nipocalimab-aahu (Imaavy) is a recently FDA-approved monoclonal antibody, and Aetna's update to CPB 1083 establishes the coverage policy framework your team needs before billing. The policy does not list specific CPT or HCPCS codes in the available data — we'll address that directly in the codes section below. If you bill for specialty biologics, hemolytic disease of the fetus and newborn (HDFN), or generalized myasthenia gravis (gMG), this policy is directly in your wheelhouse.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Nipocalimab-aahu (Imaavy) — CPB 1083
Policy Code	CPB 1083
Change Type	Modified
Effective Date	April 2, 2026
Impact Level	High
Specialties Affected	Neurology, Maternal-Fetal Medicine, Hematology, Specialty Pharmacy, Infusion Billing
Key Action	Confirm prior authorization requirements and medical necessity documentation before submitting claims for nipocalimab-aahu

---

Aetna Nipocalimab-aahu Coverage Criteria and Medical Necessity Requirements 2026

Aetna's CPB 1083 coverage policy for nipocalimab-aahu (Imaavy) reflects the drug's two FDA-approved indications. The FDA approved nipocalimab-aahu in 2025 for two distinct populations: adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, and for reducing the risk of severe hemolytic disease of the fetus and newborn (HDFN) in alloimmunized pregnant individuals.

Those are narrow, well-defined populations. That's actually good news for billing teams — narrow criteria mean less ambiguity when documenting medical necessity. The challenge is that biologics with dual indications often trigger additional scrutiny at the prior authorization stage, and nipocalimab-aahu is no exception.

Generalized Myasthenia Gravis (gMG) Indication

For the gMG indication, Aetna's medical necessity standard typically requires confirmation of AChR antibody-positive status. This is not a drug for seronegative gMG. Expect Aetna to require documented lab results confirming antibody status as part of the prior authorization submission.

Patients will also likely need to show inadequate response to, or intolerance of, conventional therapies — typically acetylcholinesterase inhibitors and at least one immunosuppressive agent. That standard step-therapy requirement is consistent with how Aetna handles other late-line biologics for neuromuscular disease. Build your prior auth packet with that documentation from the start, not as an afterthought.

Hemolytic Disease of the Fetus and Newborn (HDFN) Indication

The HDFN indication is more specialized. Nipocalimab-aahu works by reducing maternal IgG antibodies that cross the placenta and attack fetal red blood cells. Coverage under this indication applies to alloimmunized pregnant individuals at risk for severe fetal anemia.

This indication sits squarely in maternal-fetal medicine. Your billing team should expect Aetna to require documentation of alloimmunization status, prior pregnancy history, and fetal monitoring data as part of any prior authorization request. The reimbursement pathway for infusion in this population will likely route through your facility or infusion center billing — not the physician professional fee alone.

Prior Authorization for Nipocalimab-aahu Under CPB 1083

Prior authorization is expected for both indications under this coverage policy. Aetna requires prior auth for virtually all specialty biologics administered by infusion, and nipocalimab-aahu is administered intravenously. Don't submit a claim without a confirmed auth number.

The effective date of April 2, 2026 means this policy is already live. If your practice has started infusing nipocalimab-aahu without confirming Aetna's authorization requirements against CPB 1083 specifically, pull those claims and verify before they hit adjudication.

---

Aetna Nipocalimab-aahu Exclusions and Non-Covered Indications

The policy data available does not include a detailed exclusions list. That said, based on the drug's FDA labeling and Aetna's standard approach to specialty biologics, you can anticipate that off-label use will not be covered without significant additional documentation — and likely not at all under the initial policy.

Use outside the two FDA-approved indications (AChR antibody-positive gMG and HDFN prevention) will almost certainly be classified as experimental or investigational by Aetna under CPB 1083. Submit claims only for the approved indications unless you have a specific coverage determination or clinical exception approval in hand.

Seronegative gMG — meaning patients without detectable AChR antibodies — is not an approved indication. Submitting claims for that population is a fast route to a claim denial. If your neurologist is considering nipocalimab-aahu for a seronegative patient, that conversation needs to happen with your compliance officer before any infusion is scheduled.

---

Coverage Indications at a Glance

---

Aetna Nipocalimab-aahu Billing Guidelines and Action Items 2026

The policy is live as of April 2, 2026. Here's what your billing team should do right now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Nipocalimab-aahu Under CPB 1083

The available policy data for CPB 1083 does not list specific CPT, HCPCS, or ICD-10 codes. This is common for newly approved biologics — the HCPCS coding process lags FDA approval, and payer policy documents sometimes publish before permanent codes are assigned.

Here's what to do in the absence of listed codes:

Finding the correct HCPCS J-code: CMS assigns permanent J-codes to biologics on a quarterly basis. Check the CMS HCPCS Level II quarterly update for the quarter following nipocalimab-aahu's FDA approval. Your specialty pharmacy or GPO contract should also have current coding guidance.

Until a permanent J-code is assigned: You may need to bill using a not-otherwise-classified drug code (typically J3490 or J3590 for physician-administered drugs, or C9399 for new drugs billed in hospital outpatient settings pending a permanent code). Confirm which NOC code Aetna accepts for nipocalimab-aahu by calling provider services directly — different payers accept different NOC codes, and submitting the wrong one is a preventable denial.

ICD-10-CM codes to support medical necessity:

• G70.01 — Myasthenia gravis with (acute) exacerbation
• G70.00 — Myasthenia gravis without (acute) exacerbation
• O36.0190 / O36.0990 (and related codes in the O36 category) — Maternal care for rhesus isoimmunization / other blood-group isoimmunization (use the most specific code available based on trimester and fetus designation)

These ICD-10 codes are provided based on the drug's FDA-approved indications and standard coding practice — they are not extracted from the CPB 1083 policy document, which did not include code data. Confirm appropriate diagnosis coding with your coding team and verify against Aetna's billing guidelines before submitting.

If you're not sure how to code nipocalimab-aahu billing for your specific patient population, loop in your billing consultant before the effective date causes a backlog of unresolved claims.

---